A Novel GNAS1 Mutation, R201G, in McCune–Albright Syndrome
M. Riminucci,L. Fisher,Adesola Majolagbe,A. Corsi,R. Lala,C. de Sanctis,P. Robey,P. Bianco
DOI: https://doi.org/10.1359/jbmr.1999.14.11.1987
IF: 6.39
1999-11-01
Journal of Bone and Mineral Research
Abstract:ACTIVATING MISSENSE mutations of the GNAS1 gene, encoding the alpha subunit of the stimulatory G protein, Gs, have been identified in patients with the McCune– Albright syndrome (MAS, characterized by polyostotic fibrous dysplasia [FD], café au lait skin pigmentation, and endocrine disorders). The reduced GTPase activity of the mutated protein leads to overstimulation of adenylyl cyclase. Recent studies on the nature of FD suggest that the excess generation of cAMP resulting from activity of the mutated Gs alpha may represent a common (albeit not necessarily the only) pathogenetic mechanism for the diverse, skeletal, and nonskeletal manifestations of MAS. Similar mutations of the GNAS1 gene also occur in nonMAS associated FD of bone. MAS was diagnosed in an 8-year-old male presenting with precocious puberty, facial deformities, and typical café au lait spots with a “coast of Maine” profile. Extensive involvement of the cranial vault was apparent on X-ray examination, and a sample of parietal bone demonstrated changes typical of the sclerotic/pagetoid variant of FD. The craniofacial lesions were apparently progressive and were treated with pamidronate which was reported to reduce bone pain as well as to normalize the levels of serum alkaline phosphatase, osteocalcin, and hydroxyproline. At the age of 13, acromegalic bone changes and growth hormone oversecretion were detected. Genomic DNA was extracted from a surgical sample of the FD parietal bone that was obtained under an institutionally approved protocol for the use of human tissue in research (National Institutes of Health Protocol #97-DK0055). Mutation analysis was performed by sequencing the polymerase chain reaction (PCR) amplification product (exon 8) in both directions and by sequencing the PCR product obtained with peptide nucleic acid (PNA) inhibition of the normal allele amplification, a novel highly sensitive method especially suited for mutation analysis of mosaic populations. With both assays, a novel C → G (R201G) mutation was detected (Fig. 1). With the exception of a single case (of polyostotic FD) in which an R201S mutation was identified previously, R201C and R201H have been the mutations found consistently in MAS patients and in non-MAS FD of bone. Thus, of the predicted missense mutations of codon 201, only R201P and R201L remain undetected to date (although R201L has been observed in an isolated, non-MAS endocrine tumor (Table 1). The diversity of the amino acids encoded by the missense mutations detected so far (basic, uncharged polar, nonpolar) demonstrates that substitution of the R201 per se, rather than the characteristics of the substituting amino acid, is the critical molecular event leading to reduced GTPase activity. It is thought that R201 is an essential component of the “timing device” that regulates GTPase. Bourne et al. have reported that two of the single-point missense mutations in R201 of Gs alpha (R201C and R201H), as found in human tumors, appear to have reduced kcat-GTP, although the methodology and exact values were not presented. They further reported as a personal communication, the work of A.G. Gilman’s laboratory in which replacement of the R201 with mutations requiring more than one base pair changes (Val, Ala, Lys, and Glu) in bacterial recombinant Gs alpha also had reduced kcatGTP. To our knowledge, the kcat-GTP activity of the remaining single base pair missense mutations (Gly, Ser, Leu, and Pro) have not been studied. Nevertheless, the loss of the highly basic side chain of arginine (which can also be ADP-